These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 18463792)
1. Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer. Stover DG; Lockhart AC; Berlin JD; Chan E; Sandler AB; Sosman JA; Middlebrook V; Nicol S; Rothenberg ML Invest New Drugs; 2008 Aug; 26(4):339-45. PubMed ID: 18463792 [TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors. Misset JL; Gamelin E; Campone M; Delaloge S; Latz JE; Bozec L; Fumoleau P Ann Oncol; 2004 Jul; 15(7):1123-9. PubMed ID: 15205208 [TBL] [Abstract][Full Text] [Related]
3. A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer. Fury MG; Haque S; Stambuk H; Shen R; Carlson D; Pfister D Cancer; 2011 Feb; 117(4):795-801. PubMed ID: 20922785 [TBL] [Abstract][Full Text] [Related]
4. A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer. Hensley ML; Larkin J; Fury M; Gerst S; Tai DF; Sabbatini P; Konner J; Orlando M; Goss TL; Aghajanian CA Clin Cancer Res; 2008 Oct; 14(19):6310-6. PubMed ID: 18829514 [TBL] [Abstract][Full Text] [Related]
5. Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248. Alberts SR; Kim GP; Mahoney MR; Gornet MK; Rubin J; Ames M; Goetz MP; Weinshilboum RM; Nicol SJ; Goldberg RM Clin Colorectal Cancer; 2007 Jul; 6(8):572-7. PubMed ID: 17681103 [TBL] [Abstract][Full Text] [Related]
6. Pemetrexed in advanced colorectal cancer. Louvet C; de Gramont A Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):56-62. PubMed ID: 15655939 [TBL] [Abstract][Full Text] [Related]
7. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer. Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335 [TBL] [Abstract][Full Text] [Related]
8. Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer. Hoff PM; Saad ED; Pazdur R; Wolff R; Lassere Y; Bogaard KR; Abbruzzese JL Invest New Drugs; 2004 Aug; 22(3):307-13. PubMed ID: 15122078 [TBL] [Abstract][Full Text] [Related]
9. Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck. Vermorken JB; Licitra L; Stöhlmacher-Williams J; Dietz A; Lopez-Picazo JM; Hamid O; Hossain AM; Chang SC; Gauler TC Eur J Cancer; 2013 Sep; 49(13):2877-83. PubMed ID: 23726971 [TBL] [Abstract][Full Text] [Related]
10. Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. Wu XY; Huang XE; You SX; Lu YY; Cao J; Liu J Asian Pac J Cancer Prev; 2013; 14(3):2019-22. PubMed ID: 23679311 [TBL] [Abstract][Full Text] [Related]
11. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer. Dittrich C; Petruzelka L; Vodvarka P; Gneist M; Janku F; Kysela T; Melemed A; Latz J; Simms L; Krejcy K Clin Cancer Res; 2006 Dec; 12(23):7071-8. PubMed ID: 17145830 [TBL] [Abstract][Full Text] [Related]
12. A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer. Ellis PM; Chu QS; Leighl N; Laurie SA; Fritsch H; Gaschler-Markefski B; Gyorffy S; Munzert G Clin Lung Cancer; 2013 Jan; 14(1):19-27. PubMed ID: 22658814 [TBL] [Abstract][Full Text] [Related]
13. Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer. Mir O; Boudou-Rouquette P; Giroux J; Chapron J; Alexandre J; Gibault L; Ropert S; Coriat R; Durand JP; Burgel PR; Dusser D; Goldwasser F Lung Cancer; 2012 Jul; 77(1):104-9. PubMed ID: 22364783 [TBL] [Abstract][Full Text] [Related]
14. Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer. Argiris A; Karamouzis MV; Smith R; Kotsakis A; Gibson MK; Lai SY; Kim S; Branstetter BF; Shuai Y; Romkes M; Wang L; Grandis JR; Ferris RL; Johnson JT; Heron DE Ann Oncol; 2011 Nov; 22(11):2482-2488. PubMed ID: 21363880 [TBL] [Abstract][Full Text] [Related]
15. Phase II study of pemetrexed plus oxaliplatin for platinum-resistant advanced or metastatic non-small cell lung cancer patients. Lee DH; Choi CM; Kim SW; Suh C; Lee JS Med Oncol; 2012 Jun; 29(2):640-3. PubMed ID: 21499804 [TBL] [Abstract][Full Text] [Related]
16. Phase I study of carboplatin combined with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer. Takeoka H; Yamada K; Azuma K; Zaizen Y; Yamashita F; Yoshida T; Naito Y; Okayama Y; Miyamoto M; Hoshino T Jpn J Clin Oncol; 2014 May; 44(5):472-8. PubMed ID: 24688087 [TBL] [Abstract][Full Text] [Related]
17. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors. Infante JR; Novello S; Ma WW; Dy GK; Bendell JC; Huff A; Wang Q; Suttle AB; Allen R; Xu CF; Ottesen LH; Burris HA; Adjei AA Invest New Drugs; 2013 Aug; 31(4):927-36. PubMed ID: 23179337 [TBL] [Abstract][Full Text] [Related]
18. Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study. Celio L; Sternberg CN; Labianca R; La Torre I; Amoroso V; Barone C; Pinotti G; Cascinu S; Di Costanzo F; Cetto GL; Bajetta E Ann Oncol; 2009 Jun; 20(6):1062-7. PubMed ID: 19218305 [TBL] [Abstract][Full Text] [Related]
19. Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer. Clark JI; Greene JB; Lau Clark A; Dalal JS; Hofmeister CC Med Oncol; 2013 Mar; 30(1):358. PubMed ID: 23266940 [TBL] [Abstract][Full Text] [Related]
20. Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program. Atkins JN; Jacobs SA; Wieand HS; Smith RE; John WJ; Colangelo LH; Vogel VG; Kuebler JP; Cescon TP; Miller BJ; Geyer CE; Wolmark N Clin Colorectal Cancer; 2005 Sep; 5(3):181-7. PubMed ID: 16197621 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]